Erste Asset Management GmbH decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 39.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,915 shares of the life sciences company's stock after selling 22,667 shares during the quarter. Erste Asset Management GmbH's holdings in Illumina were worth $2,790,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the company. Moors & Cabot Inc. grew its holdings in shares of Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock valued at $465,000 after buying an additional 145 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock worth $445,000 after purchasing an additional 164 shares during the last quarter. Probity Advisors Inc. boosted its holdings in Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after purchasing an additional 224 shares during the last quarter. Xponance Inc. boosted its holdings in Illumina by 1.0% in the first quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock worth $2,123,000 after purchasing an additional 264 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on ILMN shares. Piper Sandler dropped their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. JPMorgan Chase & Co. dropped their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Evercore ISI raised their target price on shares of Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Barclays raised their target price on shares of Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Finally, Daiwa America cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $124.58.
Read Our Latest Report on Illumina
Illumina Price Performance
NASDAQ ILMN traded down $2.14 on Monday, reaching $99.66. The company had a trading volume of 1,686,401 shares, compared to its average volume of 2,333,490. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $15.32 billion, a PE ratio of 12.62, a price-to-earnings-growth ratio of 2.29 and a beta of 1.37. The firm's 50 day moving average price is $98.18 and its 200 day moving average price is $88.64. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories

Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.